Neon Therapeutics Announces Acceptance of European Clinical Trial Authorization Application for NEO-PTC-01
30. April 2020 07:00 ET
|
Neon Therapeutics, Inc.
CAMBRIDGE, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN) today announced the acceptance of its Clinical Trial Authorization (CTA) from the Dutch Health Authority...
Neon Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
02. März 2020 07:00 ET
|
Neon Therapeutics, Inc.
CAMBRIDGE, Mass., March 02, 2020 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN) today reported financial results for the fourth quarter and full-year ended December 31, 2019 and provided...
BioNTech to acquire Neon to strengthen global leadership position in T cell therapies
16. Januar 2020 07:30 ET
|
Neon Therapeutics, Inc.
Further expands BioNTech’s growing CAR-T and TCR therapy pipeline through addition of neoantigen specific cell therapies, including a T cell therapy targeting shared RAS oncogenesAccelerates...
Neon Therapeutics Submits European Clinical Trial Authorization Application for Personal Neoantigen-Targeted T Cell Therapy NEO-PTC-01
18. Dezember 2019 08:01 ET
|
Neon Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN) today announced that it has filed a Clinical Trial Authorization (CTA) with the Dutch Health Authority for...
Neon Therapeutics Announces New Strategic Focus on Novel T Cell Programs
20. November 2019 16:05 ET
|
Neon Therapeutics, Inc.
Lead program, NEO-PTC-01, is a personalized neoantigen adoptive T cell therapy candidate to address refractory solid tumors Corporate restructuring effected to focus resources while exploring...
Neon Therapeutics Reports Third Quarter 2019 Financial Results and Recent Highlights
12. November 2019 07:00 ET
|
Neon Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today reported...
Neon Therapeutics Announces Updated Data Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting
08. November 2019 07:00 ET
|
Neon Therapeutics, Inc.
Updated Results from NT-001 Trial of NEO-PV-01 Demonstrate Prolonged Progression-Free and Overall Survival vs. Historical Benchmark Data Advanced Process Development Supports Clinical Trial...
Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific Neoantigens
05. September 2019 16:01 ET
|
Neon Therapeutics, Inc.
Proprietary class II prediction tool achieved up to a 61-fold improvement in predicting MHC class II peptides compared to standard methods Proprietary capabilities to be integrated into Neon’s RECON®...
Neon Therapeutics Reports Second Quarter 2019 Financial Results
06. August 2019 07:00 ET
|
Neon Therapeutics, Inc.
Planning to present more detailed data from NT-001 clinical trial evaluating NEO-PV-01 in advanced or metastatic melanoma, non-small cell lung and bladder cancers at an upcoming medical society...
Neon Therapeutics’ Personal Neoantigen Vaccine Study Demonstrates Prolonged Progression-Free Survival in Advanced or Metastatic Melanoma, Non-Small Cell Lung and Bladder Cancers
15. Juli 2019 06:00 ET
|
Neon Therapeutics, Inc.
NEO-PV-01, in combination with OPDIVO® (nivolumab), broadens the immune response to specific new cancer targets, leading to the first demonstration of improved clinical durability for a personal...